Sanofi axes development of oral TNF inhibitor as monotherapy following Phase II fail
Sanofi will halt the development of its oral tumour necrosis factor (TNF) inhibitor balinatunfib as a monotherapy after it failed…
Immunology
-
-
Vertex halts development of diabetes cell therapy after trial failure
Vertex Pharmaceuticals has discontinued the development of VX-264, a type 1 diabetes (T1D) cell therapy delivered via an implantable device,…
-
J&J and Protagonist’s icotrokinra scores in Phase IIb UC study
Johnson & Johnson (J&J) and Protagonist Therapeutics’s joint interleukin-23 (IL-23) inhibitor, icotrokinra, has met the primary endpoint in a Phase…
-
Merck KGaA’s lupus drug fails in SLE cohort of Phase II trial
Merck KGaA’s oral TLR7/8 inhibitor enpatoran has failed to meet the primary endpoint in a subgroup of patients, but development…
-
Genentech eyes lupus market for Gazyva with positive Phase III data readout
Roche’s subsidiary Genentech has shared positive Phase III data with the US Food and Drug Administration (FDA) as the company…
-
Sanofi to increase competition in atopic dermatitis market after Dupixent success
Sanofi's participation at the JP Morgan 43rd Annual Healthcare Conference on 14 January 2025 was marked by a comprehensive overview…
-
Nuvig secures $161m financing to support clinical studies for NVG-2089
Nuvig Therapeutics has closed a $161m Series B financing round to advance its preclinical pipeline and support NVG-2089’s clinical proof-of-concept…
-
Kezar struck again with second FDA hold
Kezar Life Sciences has been handed a second clinical hold by the US Food and Drug Administration (FDA) in as…
-
RAPT Therapeutics shares tumble by 48% after zelnecirnon programme cull
RAPT Therapeutics has called it quits on a clinical programme evaluating zelnecirnon (RPT193) in inflammatory disorders following feedback with the…
-
AstraZeneca and Amgen’s Tezspire succeeds in Phase III nasal polyps trial
AstraZeneca and Amgen have released topline data from a Phase III trial of its inflammatory therapy, Tezspire (tezepelumab) in patients…
